| P50 | author | Carl H. June | Q19277113 |
| | Simon F Lacey | Q56978267 |
| P2093 | author name string | Fang Chen | |
| | Marcela V Maus | |
| | Jihyun Lee | |
| | Yangbing Zhao | |
| | Joseph A Fraietta | |
| | Christopher C Kloss | |
| | Jan Joseph Melenhorst | |
| | Aaron Zhang | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 |
| | T cell exclusion, immune privilege, and the tumor microenvironment | Q28259872 |
| | Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor | Q28507865 |
| | STRING v10: protein-protein interaction networks, integrated over the tree of life | Q29615545 |
| | Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer | Q29616379 |
| | Immunosuppressive strategies that are mediated by tumor cells | Q29636247 |
| | TGF-β activation and function in immunity | Q33566661 |
| | Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells | Q34094070 |
| | Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells | Q35328354 |
| | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Q35567212 |
| | Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition | Q35673845 |
| | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors | Q35690389 |
| | Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor | Q36368533 |
| | The central role of CD4(+) T cells in the antitumor immune response | Q36401381 |
| | Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region | Q36826768 |
| | Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody | Q38378054 |
| | Current status of chimeric antigen receptor therapy for haematological malignancies | Q38631108 |
| | Is autoimmunity the Achilles' heel of cancer immunotherapy? | Q38687375 |
| | Neoantigen landscape dynamics during human melanoma-T cell interactions | Q38761397 |
| | Elements of cancer immunity and the cancer-immune set point | Q39094764 |
| | The Principles of Engineering Immune Cells to Treat Cancer | Q39130457 |
| | Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. | Q39385892 |
| | The Diagnosis and Treatment of Prostate Cancer: A Review | Q39401053 |
| | In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy | Q39559727 |
| | Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors | Q39870613 |
| | Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor | Q39984618 |
| | T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma | Q40096913 |
| | Therapeutic T cell engineering | Q40199809 |
| | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. | Q40248504 |
| | Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. | Q41657338 |
| | T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine | Q42321830 |
| | PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. | Q42363154 |
| | Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 |
| | Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods | Q44041772 |
| | Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma | Q47218634 |
| | Power and sample size calculations for studies involving linear regression | Q47273484 |
| | Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen | Q47579137 |
| | Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells | Q48021661 |
| | PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis | Q49971132 |
| | Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. | Q50775718 |
| | Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease | Q73542905 |
| P433 | issue | 7 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1855-1866 | |
| P577 | publication date | 2018-05-08 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication | |
| P478 | volume | 26 | |